ArticleJournal of neurophysiology2025
Activity of protein kinase C controls the efficacy of cannabinoid receptor type 1 in the medial prefrontal cortex after neuropathic pain.
Article in Journal of neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Many patients with chronic pain conditions suffer from depression. In our previous report, we found that afferent noxious inputs after painful nerve injury compromise activity-dependent endocannabinoid (eCB) signaling in the medial prefrontal cortex (mPFC), resulting in depression. Since protein kinase C (PKC) and cAMP/protein kinase A (PKA) pathways can regulate eCB receptor type-1 (CB1R)-mediated synaptic transmission, we explored the possible roles of PKC and PKA in causing reduced eCB signaling in neuropathic pain (spared nerve injury, SNI). Four weeks after SNI, rats developed both depression and hypersensitivity of the plantar skin to punctate mechanical stimulation. Radioligand-based assay of CB1R binding in the harvested mPFC tissue showed no change after SNI in both male and female rats. Slice electrophysiological recordings from the mPFC showed that SNI did not alter the effects of a PKA agonist (forskolin) or blocker (H-89) on evoked inhibitory postsynaptic currents (eIPSCs). However, the PKC blocker chelerythrine (CHEL) fully prevented the inhibitory effect of the CB1R agonist (WIN-55212-2) on eIPSCs, whereas PKC activation with phorbol 12-myristate 13-acetate reversed the reduced effect of WIN-55212-2 on eIPSC and miniature IPSC after SNI. Together, these data suggest that PKC activity controls the efficacy of CB1Rs in mPFC after neuropathic pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.